HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Long-term adrenomedullin administration in experimental heart failure.

Abstract
Short-term administration of adrenomedullin, a recently discovered peptide with potent vasodilator, natriuretic, and aldosterone-inhibitory actions, has beneficial effects in experimental and clinical heart failure. The effects of prolonged adrenomedullin administration have not previously been assessed in this setting. Consequently, in 16 sheep with pacing-induced heart failure, we infused either adrenomedullin (10 ng/kg per minute; n=8) or a vehicle control (Hemaccel; n=8) for 4 days. Compared with control data, infusion of adrenomedullin persistently increased circulating levels of the peptide (by approximately 9.5 pmol/L; P<0.001), in association with prompt (15 minutes) and sustained (4 days) increases in cardiac output (day 4, 27%), and reductions in peripheral resistance (30%), mean arterial pressure (13%), and left atrial pressure (24%; all, P<0.001). Adrenomedullin also significantly enhanced urinary sodium excretion (day 4, 3-fold; P<0.05), creatinine excretion (1.2-fold; P<0.001), and creatinine clearance (1.4-fold; P<0.001) over the 4 days of treatment, whereas urine volume and cAMP excretion tended to be elevated (both, 0.1>P>0.05). Plasma renin activity was increased (P<0.05), whereas aldosterone levels were reduced in a sustained fashion (P<0.01). Plasma endothelin rose transiently (hours 1 to 6) after initiation of treatment (P<0.05). Despite substantial cardiac unloading, plasma concentrations of the natriuretic peptides were not significantly different from control. In conclusion, long-term administration of adrenomedullin induces pronounced and sustained cardiovascular and renal effects in experimental heart failure, including reductions in cardiac preload and afterload, as well as augmentation of cardiac output, sodium excretion, and glomerular filtration. These findings support the concept of adrenomedullin as a protective hormone during hemodynamic compromise with therapeutic potential in heart failure.
AuthorsMiriam T Rademaker, Chris J Charles, Eric A Espiner, M Gary Nicholls, A Mark Richards
JournalHypertension (Dallas, Tex. : 1979) (Hypertension) Vol. 40 Issue 5 Pg. 667-72 (Nov 2002) ISSN: 1524-4563 [Electronic] United States
PMID12411460 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Endothelins
  • Peptides
  • Natriuretic Peptide, Brain
  • Adrenomedullin
  • Aldosterone
  • Atrial Natriuretic Factor
  • Cyclic AMP
  • Renin
  • Hydrocortisone
Topics
  • Adrenomedullin
  • Aldosterone (blood)
  • Animals
  • Atrial Natriuretic Factor (blood)
  • Blood Pressure (drug effects)
  • Cardiac Output (drug effects)
  • Cardiac Pacing, Artificial (adverse effects)
  • Cyclic AMP (blood)
  • Disease Models, Animal
  • Endothelins (blood)
  • Female
  • Heart Failure (drug therapy, physiopathology)
  • Hemodynamics (drug effects)
  • Hydrocortisone (blood)
  • Infusions, Intravenous
  • Kidney (drug effects, physiology)
  • Natriuretic Peptide, Brain (blood)
  • Peptides (administration & dosage, blood)
  • Renin (blood)
  • Sheep
  • Time
  • Treatment Outcome
  • Vascular Resistance (drug effects)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: